Ross Walenga, Ph.D. (he/him/his)

US Food and Drug Administration

Poster(s):

• (T1530-08-54) Critical Formulation Attributes of Naloxone Nasal Spray Products Affecting Nasal Permeation
  Tuesday, October 24, 2023

  3:30 PM – 4:30 PM ET

• (T1030-10-66) Identifying Critical Parameters for Physiological Based Pharmacokinetic Modeling of Naloxone Hydrochloride Nasal Sprays
  Tuesday, October 24, 2023

  10:30 AM – 11:30 AM ET

• (T1530-10-68) In Silico Predictive Modeling of the Pharmacokinetic (PK) Profiles of Nasal Sprays in Adults and Children
  Tuesday, October 24, 2023

  3:30 PM – 4:30 PM ET

• (M1330-01-07) Understanding the Relationship Between In Vitro Nasal Spray Characteristics and Intranasal Deposition in the Adult and Pediatric Populations
  Monday, October 23, 2023

  1:30 PM – 2:30 PM ET